Predicting the Probability of Relapse Following Omalizumab Dose Reduction in Patients with Chronic Urticaria

Aim: Developing a predictive model for assessing the risk of relapse following Omalizumab dose reduction in patients with Chronic Urticaria

Secondary Objectives:

  • Determining the association between purported predictors of relapse and relapse occurrence following Omalizumab dose reduction in patients with Chronic Urticaria
  • Determining the non-linear effect of predictors of relapse following Omalizumab dose reduction in patients with Chronic Urticaria with the help of machine learning
  • Performing a logistic regression analysis to determine which features are independently associated with a lower/higher probability of relapse following Omalizumab dose reduction after remission in patients with Chronic Urticaria
Project lead: Dr. Maryam KhoshkhuiProject advisor: Emek Kocatürk, Ana Maria Giménez-ArnauSteering committee: Emek Kocatürk, Ana Giménez-Arnau, Kiran Godse, Murat Türk, Luis Ensina, Simon Francis ThomsenStatus: Global Rollout
Deadline: We need to get your treatment phase data by 30.03.2025, step-down phase data by 30.10.2025, and follow-up phase data by 30.02.2026.

If you have any questions and want to participate, please reach out to Maryam Khoshkhui at khoshkhuim(at)mums.ac.ir or Mehraneh Movahedi at  Mehraneh.m1997ATgmail.com.

Learn about other projects